CMPS

#1736
COMPASS Pathways Plc - American Depository Shares
13.0 6 USD
+9.56%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
13.06
13.06
Faixa anual
0.12
13.06
Mudança diária
+9.56%
Mudança mensal
+54.37%
Mudança em 6 meses
+138.32%
Mudança anual
+105.02%
Fechamento anterior
11.9 2
Open
13.0 6
Mínimo
13.0 6
High
13.0 6
Volume
59
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
Demonstração de resultados Balanço patrimonial Fluxo de caixa
Valor Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26 TTM

COMPASS Pathways Plc - American Depository Shares

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine. Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use.

Notícias